VS-5584 Inhibits Human Osteosarcoma Cells Growth by Induction of G1-phase Arrest through Regulating PI3K/mTOR and MAPK Pathways.

CONCLUSIONS: Our findings validated that VS-5584 may be a promising anticancer agent with potential application in the chemotherapy and chemoprevention of human osteosarcoma. PMID: 32286946 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32286946?dopt=Abstract

Source: Current Cancer Drug Targets - April 13, 2020 Category: Cancer & Oncology Authors: Sun JY, Hou YJ, Cui HJ, Zhang C, Yang MF, Wang FZ, Sun Z, Fan CD, Sun BL, Oh JR Tags: Curr Cancer Drug Targets Source Type: research